SkinBioTherapeutics Management
Management criteria checks 1/4
SkinBioTherapeutics' CEO is Stuart Ashman, appointed in Jul 2019, has a tenure of 4.83 years. total yearly compensation is £382.48K, comprised of 95.1% salary and 4.9% bonuses, including company stock and options. directly owns 0.14% of the company’s shares, worth £25.60K. The average tenure of the management team and the board of directors is 1.5 years and 5 years respectively.
Key information
Stuart Ashman
Chief executive officer
UK£382.5k
Total compensation
| CEO salary percentage | 95.1% |
| CEO tenure | 4.8yrs |
| CEO ownership | 0.1% |
| Management average tenure | 1.5yrs |
| Board average tenure | 5yrs |
Recent management updates
Recent updates
Here's Why We're Watching SkinBioTherapeutics' (LON:SBTX) Cash Burn Situation
Mar 28
Will SkinBioTherapeutics (LON:SBTX) Spend Its Cash Wisely?
Sep 30Is SkinBioTherapeutics (LON:SBTX) In A Good Position To Deliver On Growth Plans?
Jun 11We Think SkinBioTherapeutics (LON:SBTX) Can Afford To Drive Business Growth
Feb 16We're Not Worried About SkinBioTherapeutics' (LON:SBTX) Cash Burn
Sep 29Companies Like SkinBioTherapeutics (LON:SBTX) Can Afford To Invest In Growth
Mar 23How Much Are SkinBioTherapeutics Plc (LON:SBTX) Insiders Taking Off The Table?
Jan 29Companies Like SkinBioTherapeutics (LON:SBTX) Are In A Position To Invest In Growth
Dec 07
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -UK£3m |
| Sep 30 2023 | n/a | n/a | -UK£3m |
| Jun 30 2023 | UK£382k | UK£364k | -UK£3m |
| Mar 31 2023 | n/a | n/a | -UK£3m |
| Dec 31 2022 | n/a | n/a | -UK£3m |
| Sep 30 2022 | n/a | n/a | -UK£3m |
| Jun 30 2022 | UK£368k | UK£319k | -UK£3m |
| Mar 31 2022 | n/a | n/a | -UK£2m |
| Dec 31 2021 | n/a | n/a | -UK£2m |
| Sep 30 2021 | n/a | n/a | -UK£2m |
| Jun 30 2021 | UK£373k | UK£323k | -UK£1m |
| Mar 31 2021 | n/a | n/a | -UK£1m |
| Dec 31 2020 | n/a | n/a | -UK£1m |
| Sep 30 2020 | n/a | n/a | -UK£1m |
| Jun 30 2020 | UK£276k | UK£234k | -UK£2m |
| Mar 31 2020 | n/a | n/a | -UK£1m |
| Dec 31 2019 | n/a | n/a | -UK£1m |
| Sep 30 2019 | n/a | n/a | -UK£1m |
| Jun 30 2019 | UK£265k | UK£52k | -UK£1m |
Compensation vs Market: Stuart's total compensation ($USD477.85K) is above average for companies of similar size in the UK market ($USD344.28K).
Compensation vs Earnings: Stuart's compensation has increased whilst the company is unprofitable.
CEO
Stuart Ashman (57 yo)
4.8yrs
Tenure
UK£382,478
Compensation
Mr. Stuart John Ashman serves as Chief Executive Officer of SkinBioTherapeutics since July 2019 and serves as Executive Director at SkinBioTherapeutics Plc since April 18, 2019. Since 2014, he served as Ch...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 4.8yrs | UK£382.48k | 0.14% £ 25.6k | |
| CFO, Secretary & Director | 1.9yrs | UK£261.48k | 0.079% £ 14.2k | |
| Head of Formulations | less than a year | no data | no data | |
| Group Financial Controller | 1.2yrs | no data | no data |
1.5yrs
Average Tenure
Experienced Management: SBTX's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 5.1yrs | UK£382.48k | 0.14% £ 25.6k | |
| CFO, Secretary & Director | 1.9yrs | UK£261.48k | 0.079% £ 14.2k | |
| Independent Non-Executive Director | 7.2yrs | UK£41.01k | 0.094% £ 16.8k | |
| Independent Non-Executive Chairman | 7.6yrs | UK£68.67k | 0.29% £ 51.8k | |
| Scientific Adviser | 4.8yrs | UK£66.42k | no data | |
| Independent Non-Executive Director | 2.1yrs | UK£25.00k | 0.023% £ 4.0k |
5.0yrs
Average Tenure
57yo
Average Age
Experienced Board: SBTX's board of directors are considered experienced (5 years average tenure).